Matinas BioPharma Holdings Inc (FRA:6LJ0)
€ 2.69 0 (0%) Market Cap: 3.23 Mil Enterprise Value: -7.02 Mil PE Ratio: 0 PB Ratio: 0.15 GF Score: 57/100

Matinas BioPharma Holdings Inc R&D Day Transcript

Jun 17, 2021 / 12:30PM GMT
Release Date Price: €37.5 (+2.04%)
Operator

Hello, and welcome to the Matinas BioPharma R&D Day Conference Call and Webcast. If you have not already done so, please close all other programs on your computer. (Operator Instructions)

I will now turn our webcast over to Jerry Jabbour, Chief Executive Officer of Matinas BioPharma. Please go ahead.

Jerome D. Jabbour
Matinas BioPharma Holdings, Inc. - Co-Founder, CEO, President & Director

Thank you, Jesse. Before I begin, I would like to remind everyone that today's presentation will include forward-looking statements. Please see Slide 3 and our SEC filings for a discussion about important risk factors relating to these forward-looking statements.

Now with that formality out of the way, good morning, and welcome to Matinas' very first R&D Day. We are delighted that you are taking the time to join us today. Today's presentations and materials come at an extremely exciting and important time for our company. Our recent strategic decision to focus our internal expertise and resources on our lipid nanocrystal, or LNC, platform and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot